At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Mar 12, 2026 at 08:00 ET
Theriva Biologics reported its 2025 financial results, highlighted by a $9.0 million contingent consideration charge tied to VCN-01's Phase 2b trial success, reduced R&D spending, and a licensing deal for SYN-020 that brings $300,000 upfront and up to $38 million in potential milestones. The company has $15.2 million in cash as of February 2026, providing runway into Q1 2027.
- VCN-01 achieved primary survival and safety endpoints in Phase 2b trial, triggering a $9.0 million contingent consideration expense
- Licensed SYN-020 to Rasayana Therapeutics for $300k upfront, up to $38M in milestones, and tiered single-digit royalties
- R&D expenses decreased 28% YoY to $8.6M due to trial completions
- General and administrative expenses doubled to $15.4M, driven by the contingent consideration adjustment
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access